Benzinga | Jul 29, 2020 06:07AM EDT

HC Wainwright & Co. Maintains Buy on Momenta Pharmaceuticals, Raises Price Target to $50

HC Wainwright & Co. analyst Douglas Tsao maintains Momenta Pharmaceuticals (NASDAQ:MNTA) with a Buy and raises the price target from $46 to $50.